StreetInsider.com News Articles

Form SCHEDULE 13G/A Roivant Sciences Ltd. Filed by: FMR LLC

Fri, 06 Mar 2026 10:05:00 -0500

si-local-file:///var/storage/secattach/20260306/26123247.html

Form SCHEDULE 13G/A Roivant Sciences Ltd. Filed by: FMR LLC

Fri, 06 Mar 2026 10:05:00 -0500

si-local-file:///var/storage/secattach/20260306/26123247.html

TD Cowen Reiterates Buy Rating and Top Pick on Roivant Sciences (ROIV)

Wed, 04 Mar 2026 08:36:47 -0500

TD Cowen analyst Yaron Werber reiterated a Buy rating and $38.00 price target on Roivant Sciences (NASDAQ: ROIV).

The analyst commented: "Brepo DM Launch In Sept + Up To $2.3B Settlement Win From MRNA; ROIV announced today: (1) brepo in DM has PDUFA in Q3 (late Aug in our view) and will now launch in Sept '26 and (2) ROIV will receive up to $2.3B settlement from MRNA ($950M upfront) which is a good outcome in our view given risk of jury trials. Mgmt is also very confident in brepo's Ph3 NIU and mosli's Ph2b PH-ILD data in H2:26. Overall, we

Roivant Sciences (ROIV) PT Raised to $34 at H.C. Wainwright

Wed, 04 Mar 2026 06:42:20 -0500

(Updated - March 4, 2026 6:42 AM EST)

H.C. Wainwright analyst Douglas Tsao raised the price target on Roivant Sciences (NASDAQ: ROIV) to $34.00 (from $33.00) while maintaining a Buy rating.

The analyst commented: "Yesterday, Roivant announced that its subsidiary Genevant Sciences and Arbutus Biopharma have entered into a $2.25B global settlement with Moderna to resolve patent-infringement litigation related to Moderna’s use of Genevant/Arbutus LNP delivery technology in its COVID-19 vaccine. We see three key implications that we discuss within. We add the $2.25B litigation proceeds to our model and raise our price target to $34 from $33."

Roivant Sciences (ROIV) PT Raised to $34 at H.C. Wainwright

Wed, 04 Mar 2026 06:42:20 -0500

(Updated - March 4, 2026 6:42 AM EST)

H.C. Wainwright analyst Douglas Tsao raised the price target on Roivant Sciences (NASDAQ: ROIV) to $34.00 (from $33.00) while maintaining a Buy rating.

Wolfe Research Reiterates Outperform Rating on Roivant Sciences (ROIV)

Tue, 03 Mar 2026 17:30:57 -0500

Wolfe Research analyst Andy Chen reiterated an Outperform rating and $30.00 price target on Roivant Sciences (NASDAQ: ROIV)

The analyst commented, "As a result of a confidential discussion, Moderna to pay Genevant & Arbutus $950M upfront (payable in July), with $1.3B cash contingent on a Section 1498 decision (a narrow legal argument and the only appealable aspect of the case, and Gline is optimistic regarding prospects here). CEO pre-emptively answered the question of 'why not more?' and highlights that this $2.25B is already the largest amount seen in the history of pharmaceutical patent litigation. A smaller piece of news: brepocitinib receives

After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more

Tue, 03 Mar 2026 16:33:03 -0500

After-hours movers:

Moderna (NASDAQ: MRNA) rose 10%, Roivant Sciences (NASDAQ: ROIV) rose 6% and Arbutus Biopharma (NASDAQ: ABUS) rose 15% after a $2.25 billion global settlement to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax

CrowdStrike (NASDAQ: CRWD) fell 1.25% after in-line quarterly results and guidance. Total revenue was $1.31 billion, a 23% increase, compared to $1.06 billion in the fourth quarter of fiscal 2025.